EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Fulgent Genetics's enterprise value is $188.2 Mil.
Fulgent Genetics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $289.2 Mil. Therefore, Fulgent Genetics's EV-to-Revenue for today is 0.65.
The historical rank and industry rank for Fulgent Genetics's EV-to-Revenue or its related term are showing as below:
FLGT'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.46 Med: 2.55 Max: 24.73
Current: 0.65
During the past 10 years, the highest EV-to-Revenue of Fulgent Genetics was 24.73. The lowest was 0.46. And the median was 2.55.
FLGT's EV-to-Revenue is ranked better than 87.17% of 226
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.07
vs FLGT: 0.65
As of today (2024-04-26), Fulgent Genetics's stock price is $20.22.
Fulgent Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $9.71. Therefore, Fulgent Genetics's PS Ratio for today is 2.08.
Fulgent Genetics EV-to-Revenue Historical Data
The historical data trend for Fulgent Genetics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fulgent Genetics's EV-to-Revenue
For the Diagnostics & Research subindustry, Fulgent Genetics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's EV-to-Revenue falls into.
Fulgent Genetics's current Enterprise Value is $188.2 Mil.
Fulgent Genetics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $289.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics's share price for today is $20.22.
Fulgent Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.71.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Fulgent Genetics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Fulgent Genetics (Fulgent Genetics) Business Description
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FLGT has been successfully added to your 